Tianda Pharmaceuticals Limited (HKG:0455)
Hong Kong · Delayed Price · Currency is HKD 0.0930
+0.0070 (8.14%)
Jun 1, 2026, 1:20 PM HKT
Tianda Pharmaceuticals Income Statement
Financials in millions HKD. Fiscal year is January - December.
Millions HKD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Mar '22 Mar 31, 2022 |
| 322.95 | 329.94 | 532.09 | 546.69 | 509.96 | |
Revenue Growth (YoY) | -2.12% | -37.99% | -2.67% | 7.20% | 7.51% |
Cost of Revenue | 189.64 | 177.91 | 276.56 | 295.17 | 268.73 |
Gross Profit | 133.31 | 152.02 | 255.53 | 251.52 | 241.22 |
Selling, General & Admin | 179.07 | 192.89 | 271.45 | 285.52 | 269.46 |
Research & Development | 8.33 | 13.28 | 13.11 | 36.15 | 15.86 |
Operating Expenses | 187.4 | 206.17 | 284.56 | 321.67 | 285.32 |
Operating Income | -54.09 | -54.15 | -29.02 | -70.14 | -44.1 |
Interest Expense | -3.53 | -4.85 | -4.95 | -6.72 | -0.73 |
Interest & Investment Income | 0.38 | 1.1 | 3.03 | 4.34 | 2.3 |
Currency Exchange Gain (Loss) | 0.23 | -0.11 | 0.48 | -0.21 | 1.07 |
Other Non Operating Income (Expenses) | 2.73 | 4.48 | 4.91 | 6.93 | 2.32 |
EBT Excluding Unusual Items | -54.28 | -53.54 | -25.55 | -65.8 | -39.13 |
Impairment of Goodwill | -14.76 | -1.34 | - | - | -1.58 |
Gain (Loss) on Sale of Investments | 0.09 | 0.64 | -0.29 | 0.7 | 0.67 |
Gain (Loss) on Sale of Assets | -0.11 | -0.1 | 0.14 | 1.25 | 12.03 |
Other Unusual Items | -0.26 | - | - | - | - |
Pretax Income | -69.33 | -54.34 | -25.69 | -63.85 | -28.02 |
Income Tax Expense | 0.93 | 7.07 | -0.69 | -4.86 | -6.34 |
Earnings From Continuing Operations | -70.25 | -61.41 | -25.01 | -58.99 | -21.68 |
Minority Interest in Earnings | 0.26 | 0.04 | 0.85 | 4.35 | 1.9 |
Net Income | -70 | -61.37 | -24.16 | -54.64 | -19.77 |
Net Income to Common | -70 | -61.37 | -24.16 | -54.64 | -19.77 |
Shares Outstanding (Basic) | 2,150 | 2,150 | 2,150 | 2,150 | 2,150 |
Shares Outstanding (Diluted) | 2,150 | 2,150 | 2,150 | 2,150 | 2,150 |
EPS (Basic) | -0.03 | -0.03 | -0.01 | -0.03 | -0.01 |
EPS (Diluted) | -0.03 | -0.03 | -0.01 | -0.03 | -0.01 |
Free Cash Flow | 7.18 | -30.3 | -99.04 | 68.63 | -61.98 |
Free Cash Flow Per Share | 0.00 | -0.01 | -0.05 | 0.03 | -0.03 |
Dividend Per Share | - | - | 0.003 | 0.003 | 0.003 |
Dividend Growth | - | - | -25.01% | 33.35% | - |
Gross Margin | 41.28% | 46.08% | 48.02% | 46.01% | 47.30% |
Operating Margin | -16.75% | -16.41% | -5.46% | -12.83% | -8.65% |
Profit Margin | -21.68% | -18.60% | -4.54% | -9.99% | -3.88% |
Free Cash Flow Margin | 2.22% | -9.18% | -18.61% | 12.55% | -12.16% |
EBITDA | -23.27 | -24.47 | -0.95 | -27.88 | -29.64 |
EBITDA Margin | -7.20% | -7.42% | -0.18% | -5.10% | -5.81% |
D&A For EBITDA | 30.82 | 29.68 | 28.07 | 42.26 | 14.46 |
EBIT | -54.09 | -54.15 | -29.02 | -70.14 | -44.1 |
EBIT Margin | -16.75% | -16.41% | -5.45% | -12.83% | -8.65% |